Cite
HARVARD Citation
Gelbenegger, G. et al. (2022). Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open‐label, extension trial. British journal of haematology. pp. e59-e62. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gelbenegger, G. et al. (2022). Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open‐label, extension trial. British journal of haematology. pp. e59-e62. [Online].